Lunger John

SEC source: 0001104659-25-015743 · tm257186-4_4seq1.xml · derivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,074,696

Underlying: Ordinary Shares · 1,074,696 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 268,674 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 268,674 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-25-015743 · tm257186-4_4seq1.xml · derivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,612,032

Underlying: Ordinary Shares · 1,612,032 shares

Expires 2035-02-20

F1 · derivative.exercise_price: The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 403,008 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 33,582 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 33,654 Ordinary Shares on February 20, 2029.

SEC source: 0001104659-25-004607 · tm253716-3_4.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,510

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.5797 to $0.589, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 163,380 ADSs and RSU-style options and other options covering an aggregate of 10,135,962 ordinary shares of the Issuer.

SEC source: 0001104659-25-003768 · tm253441-2_4seq1.xml · nonDerivative · entry 3

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,756

F7 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 15, 2024 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F8 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.57 to $0.595, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F9 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 136,156 ADSs and RSU-style options and other options covering an aggregate of 10,214,526 ordinary shares of the Issuer.

SEC source: 0001104659-25-003768 · tm253441-2_4seq1.xml · nonDerivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,623

F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.58 to $0.603, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 136,156 ADSs and RSU-style options and other options covering an aggregate of 10,214,526 ordinary shares of the Issuer.

SEC source: 0001104659-25-003768 · tm253441-2_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,845

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.58 to $0.603, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 136,156 ADSs and RSU-style options and other options covering an aggregate of 10,214,526 ordinary shares of the Issuer.

SEC source: 0001104659-24-004562 · tm243270-14_4seq1.xml · nonDerivative · entry 3

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,015

F7 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of 100% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F8 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.67 to $0.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F9 · balance_after: The ADSs reported in his Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 102,333 ADSs and RSU-style options and other options covering an aggregate of 10,495,122 ordinary shares of the Issuer.

SEC source: 0001104659-24-004562 · tm243270-14_4seq1.xml · nonDerivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,785

F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.67 to $0.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 102,333 ADSs and RSU-style options and other options covering an aggregate of 10,495,122 ordinary shares of the Issuer.

SEC source: 0001104659-24-004562 · tm243270-14_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,023

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is the sale price per ADS.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 102,333 ADSs and RSU-style options and other options covering an aggregate of 10,495,122 ordinary shares of the Issuer.

SEC source: 0001104659-24-004528 · tm243270-10_4seq1.xml · derivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 565,416

Underlying: Ordinary Shares · 565,416 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-24-004528 · tm243270-10_4seq1.xml · derivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,544,432

Underlying: Ordinary Shares · 2,544,432 shares

Expires 2034-01-15

F1 · derivative.exercise_price: The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028.

SEC source: 0001104659-24-003744 · tm243270-3_4seq1.xml · nonDerivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,874

F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.813 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 88,355 ADSs and RSU-style options and other options covering an aggregate of 7,724,982 ordinary shares of the Issuer.

SEC source: 0001104659-24-003744 · tm243270-3_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,104

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.80 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 88,355 ADSs and RSU-style options and other options covering an aggregate of 7,724,982 ordinary shares of the Issuer.

SEC source: 0001104659-23-086416 · tm2320966-2_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,718

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on August 1, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is the sale price per ADS.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 83,637 ADSs and RSU-style options and other options covering an aggregate of 7,864,224 ordinary shares of the Issuer.

SEC source: 0001104659-23-004382 · tm231655-20_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,264

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.82 to $1.87, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 76,373 ADSs and RSU-style options and other options covering an aggregate of 7,911,108 ordinary shares of the Issuer.

SEC source: 0001104659-23-004376 · tm231655-15_4seq1.xml · derivative · entry 3

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,920

Underlying: Ordinary Shares · 190,920 shares

Expires 2025-03-15

F6 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-23-004376 · tm231655-15_4seq1.xml · derivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 314,256

Underlying: Ordinary Shares · 314,256 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-23-004376 · tm231655-15_4seq1.xml · derivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,407,072

Underlying: Ordinary Shares · 1,407,072 shares

Expires 2033-01-17

F1 · derivative.exercise_price: The exercise price was converted from GBP0.26 based on an exchange rate of U.S.$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027.

SEC source: 0001104659-23-003538 · tm231655-7_4seq1.xml · nonDerivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,121

F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.70 to $1.79, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 61,982 ADSs and RSU-style options and other options covering an aggregate of 6,069,084 ordinary shares of the Issuer.

SEC source: 0001104659-23-003538 · tm231655-7_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,270

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.73 to $1.76, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 61,982 ADSs and RSU-style options and other options covering an aggregate of 6,069,084 ordinary shares of the Issuer.

SEC source: 0001104659-23-001090 · tm231655-3_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,725

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price based on prices ranging from $1.65 to $1.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 60,257 ADSs and RSU-style options and other options covering an aggregate of 6,208,326 ordinary shares of the Issuer.

SEC source: 0001104659-22-084894 · tm2222258-2_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,829

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on August 1, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.7642 to $1.7808, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 55,428 ADSs and RSU-style options and other options covering an aggregate of 6,225,276 ordinary shares of the Issuer.

SEC source: 0001104659-22-077470 · tm2220260-8_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,104

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on July 2, 2018 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.67 to $1.69, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 52,324 ADSs and RSU-style options and other options covering an aggregate of 6,272,148 ordinary shares of the Issuer.

SEC source: 0001457612-22-000009 · wf-form4_164669484940152.xml · derivative · entry 1

Lunger John · CIK 0001784487 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2032-03-03

F1 · derivative.exercise_date: The options are scheduled to vest in 36 equal monthly installments beginning on the first monthly anniversary of the grant date.

SEC source: 0001104659-22-005055 · tm221700-17_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,336

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.17 to $3.22, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 44,988 ADSs and RSU-style options and other options covering an aggregate of 6,302,610 ordinary shares of the Issuer.

SEC source: 0001104659-22-004157 · tm221700-9_4seq.xml · derivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 314,256

Underlying: Ordinary Shares · 314,256 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the twelfth of each January from January 12, 2024 through January 12, 2026.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-22-004157 · tm221700-9_4seq.xml · derivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,407,072

Underlying: Ordinary Shares · 1,407,072 shares

Expires 2032-01-12

F1 · derivative.exercise_price: The exercise price was converted from GBP0.44 based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the twelfth of each month from February 12, 2023 through December 12, 2025 and 29,454 Ordinary Shares on January 12, 2026.

SEC source: 0001104659-22-004152 · tm221700-13_4seq1.xml · nonDerivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,749

F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.53 to $3.55, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 36,896 ADSs and RSU-style options and other options covering an aggregate of 6,372,834 ordinary shares of the Issuer.

SEC source: 0001104659-22-004152 · tm221700-13_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,343

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.48 to $3.64, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 36,896 ADSs and RSU-style options and other options covering an aggregate of 6,372,834 ordinary shares of the Issuer.

SEC source: 0001104659-22-001670 · tm221700-3_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,755

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price based on prices ranging from $4.04 to $4.10, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 35,141 ADSs and RSU-style options and other options covering an aggregate of 4,729,134 ordinary shares of the Issuer.

SEC source: 0001104659-21-098959 · tm2121284-10_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,873

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on August 1, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.56 to $3.60, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 30,268 ADSs and RSU-style options and other options covering an aggregate of 4,746,084 ordinary shares of the Issuer.

SEC source: 0001104659-21-089048 · tm2121284-8_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,170

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on July 2, 2018 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.26 to $4.30, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 27,098 ADSs and RSU-style options and other options covering an aggregate of 4,792,956 ordinary shares of the Issuer.

SEC source: 0001104659-21-005545 · tm213569-2_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,346

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which vested on January 16, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.64 to $5.72, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 19,752 ADSs and RSU-style options and other options covering an aggregate of 4,823,418 ordinary shares of the Issuer.

SEC source: 0001104659-21-003592 · tm212950-3_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,767

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $6.15 to $6.22, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 17,985 ADSs and RSU-style options and other options covering an aggregate of 4,893,642 ordinary shares of the Issuer.

SEC source: 0001104659-21-003130 · tm212800-2_4seq1.xml · derivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 242,712

Underlying: Ordinary Shares · 242,712 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 60,678 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in annual installments of 60,678 Ordinary Shares on the eleventh of each January from January 11, 2023 through January 11, 2025.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-21-003130 · tm212800-2_4seq1.xml · derivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,086,816

Underlying: Ordinary Shares · 1,086,816 shares

Expires 2031-01-11

F1 · derivative.exercise_price: The exercise price was converted from GBP0.76 based on an exchange rate of U.S.$ 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 271,704 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in monthly installments of 22,638 Ordinary Shares on the eleventh of each month from February 11, 2022 through December 11, 2024 and 22,782 Ordinary Shares on January 11, 2025.

SEC source: 0001104659-21-001178 · tm211506d4_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,760

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which vested on January 4, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.265 to $5.45, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 16,225 ADSs and RSU-style options and other options covering an aggregate of 3,581,064 ordinary shares of the Issuer.

SEC source: 0001104659-20-090470 · a4.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,066

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on July 2, 2018 and which vested on July 2, 2020 and from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on August 1, 2019 and which vested on August 1, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited.

F2 · security: The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F3 · price: These ADSs were sold in multiple transactions at a price of $9.25. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F4 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 8,159 ADSs and RSU-style options and other options covering an aggregate of 3,598,014 ordinary shares of the Issuer.

SEC source: 0001104659-20-005261 · a4.xml · derivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,896

Underlying: Ordinary Shares · 280,896 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S$1.302659 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 70,224 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in annual installments of 70,224 Ordinary Shares on the sixteenth of each January from January 16, 2022 through January 16, 2024.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-20-005261 · a4.xml · derivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,257,744

Underlying: Ordinary Shares · 1,257,744 shares

Expires 2030-01-16

F1 · derivative.exercise_price: The exercise price was converted from GBP0.57 based on an exchange rate of U.S$1.302659 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 314,436 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in monthly installments of 26,202 Ordinary Shares on the sixteenth of each month from February 16, 2021 through December 16, 2023 and 26,238 Ordinary Shares on January 16, 2024.

SEC source: 0001104659-20-004421 · a4.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,681

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.12 to $5.18, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 6,478 ADSs and RSU-style options and other options covering an aggregate of 2,136,708 ordinary shares of the Issuer.

SEC source: 0001104659-20-002082 · a4.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,677

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which vested on January 4, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.20 to $1.2008, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 4,801 ADSs and RSU-style options and other options covering an aggregate of 2,153,658 ordinary shares of the Issuer.

SEC source: 0001104659-19-044061 · a4.xml · derivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,500

Underlying: Ordinary Shares · 187,500 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.22179 - GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 46,875 Ordinary Shares on August 1, 2020 and will be exercisable as to the remainder in annual installments of 46,875 Ordinary Shares on the first of each August from August 1, 2021 through August 1, 2023.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-19-044061 · a4.xml · derivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 839,568

Underlying: Ordinary Shares · 839,568 shares

Expires 2029-08-01

F1 · derivative.exercise_price: The exercise price was converted from GBP0.45 based on an exchange rate of U.S.$1.22179 - GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 209,892 Ordinary Shares on August 1, 2020 and will be exercisable as to the remainder in monthly installments of 17,490 Ordinary Shares on the first of each month from September 1, 2020 through July 1, 2023 and 17,526 Ordinary Shares on August 1, 2023.